{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:28:20Z","timestamp":1792621700839,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.biopsych.2013.12.002","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T11:23:28Z","timestamp":1386761008000},"page":"292-299","source":"Crossref","is-referenced-by-count":114,"title":["The Cytokine Model of Schizophrenia: Emerging Therapeutic Strategies"],"prefix":"10.1016","volume":"75","author":[{"given":"Ragy R.","family":"Girgis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samhita S.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2013.12.002_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: An update and critical review of the pharmacology and clinical profiles of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/ajp.151.1.20","article-title":"Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia","volume":"151","author":"Breier","year":"1994","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2013.12.002_bib6","first-page":"28","article-title":"Assessing the effects of atypical antipsychotics on negative symptoms","volume":"59","author":"Meltzer","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1176\/ajp.154.6.799","article-title":"Does risperidone improve verbal working memory in treatment-resistant schizophrenia?","volume":"154","author":"Green","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0006-3223(98)00088-2","article-title":"Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients","volume":"44","author":"Kern","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0006-3223(02)01370-7","article-title":"The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone","volume":"51","author":"Green","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib10","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1176\/appi.ajp.161.6.985","article-title":"Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol","volume":"161","author":"Keefe","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.biopsych.2005.06.022","article-title":"Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis","volume":"59","author":"Keefe","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":"The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis","volume":"25","author":"Keefe","year":"1999","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2013.12.002_bib13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/schbul\/sbq146","article-title":"Maternal infection and schizophrenia: Implications for prevention","volume":"37","author":"Brown","year":"2011","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2013.12.002_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/mp.2008.5","article-title":"Are some cases of psychosis caused by microbial agents? A review of the evidence","volume":"13","author":"Yolken","year":"2008","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1176\/appi.ajp.2009.09030361","article-title":"Prenatal infection and schizophrenia: A review of epidemiologic and translational studies","volume":"167","author":"Brown","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/archpsyc.61.8.774","article-title":"Serologic evidence of prenatal influenza in the etiology of schizophrenia","volume":"61","author":"Brown","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.biopsych.2006.05.024","article-title":"Toxoplasma gondii as a risk factor for early-onset schizophrenia: Analysis of filter paper blood samples obtained at birth","volume":"61","author":"Mortensen","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1176\/appi.ajp.162.4.767","article-title":"Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring","volume":"162","author":"Brown","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.163.5.927","article-title":"Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia","volume":"163","author":"Babulas","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib22","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/archpsyc.58.11.1032","article-title":"Maternal infections and subsequent psychosis among offspring","volume":"58","author":"Buka","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.biopsych.2007.09.022","article-title":"Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring","volume":"63","author":"Buka","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib24","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1176\/appi.ajp.163.12.2178","article-title":"No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia?","volume":"163","author":"Brown","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/schbul\/sbl050","article-title":"Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-analysis","volume":"33","author":"Torrey","year":"2007","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2013.12.002_bib26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.biopsych.2006.09.034","article-title":"Antibodies to infectious agents in individuals at ultra-high risk for psychosis","volume":"61","author":"Amminger","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1176\/appi.ajp.2007.06081254","article-title":"Selected infectious agents and risk of schizophrenia among U.S. military personnel","volume":"165","author":"Niebuhr","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib28","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1176\/appi.ajp.2011.10091351","article-title":"Toxoplasma infection and later development of schizophrenia in mothers","volume":"168","author":"Pedersen","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1176\/appi.ajp.2011.11030516","article-title":"Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study","volume":"168","author":"Benros","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0920-9964(96)00123-5","article-title":"Exposure to infection and brain development: Cytokines in the pathogenesis of schizophrenia","volume":"24","author":"Gilmore","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2013.12.002_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/brbi.1995.1026","article-title":"Regulation of the HPA axis by cytokines","volume":"9","author":"Turnbull","year":"1995","journal-title":"Brain Behav Immunity"},{"key":"10.1016\/j.biopsych.2013.12.002_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/abbi.1998.0761","article-title":"Association between oxidative stress and cytokine production in nickel-treated rats","volume":"356","author":"Chen","year":"1998","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.biopsych.2013.12.002_bib33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0029-7844(95)00189-X","article-title":"Maternal and umbilical serum concentrations of granulocyte colony-stimulating factor and its messenger RNA during clinical chorioamnionitis","volume":"86","author":"Li","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopsych.2013.12.002_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-3940(94)90933-4","article-title":"Penetration of interleukin-6 across the murine blood-brain barrier","volume":"179","author":"Banks","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.biopsych.2013.12.002_bib35","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbr.2008.12.016","article-title":"Immune involvement in schizophrenia and autism: etiology, pathology and animal models","volume":"204","author":"Patterson","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2013.12.002_bib36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/schbul\/sbn022","article-title":"A review of the fetal brain cytokine imbalance hypothesis of schizophrenia","volume":"35","author":"Meyer","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2013.12.002_bib37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.neuroscience.2008.04.031","article-title":"Preliminary evidence for a modulation of fetal dopaminergic development by maternal immune activation during pregnancy","volume":"154","author":"Meyer","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2013.12.002_bib38","doi-asserted-by":"crossref","first-page":"10695","DOI":"10.1523\/JNEUROSCI.2178-07.2007","article-title":"Maternal immune activation alters fetal brain development through interleukin-6","volume":"27","author":"Smith","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2013.12.002_bib39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1113\/jphysiol.2006.111260","article-title":"Prenatal exposure to interleukin-6 results in hypertension and alterations in the renin-angiotensin system of the rat","volume":"575","author":"Samuelsson","year":"2006","journal-title":"J Physiol"},{"key":"10.1016\/j.biopsych.2013.12.002_bib40","unstructured":"Hsiao E, Patterson PH (2009): Maternal immune activation evokes IL-6-dependent downstream signaling in the placenta and fetal brain. Program No. 436.19. Neuroscience Meeting Planner. Chicago: Society for Neuroscience."},{"key":"10.1016\/j.biopsych.2013.12.002_bib41","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bbi.2010.12.017","article-title":"Activation of the maternal immune system induces endocrine changes in the placenta via IL-6","volume":"25","author":"Hsiao","year":"2011","journal-title":"Brain Behav Immunity"},{"key":"10.1016\/j.biopsych.2013.12.002_bib42","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1523\/JNEUROSCI.0099-06.2006","article-title":"The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology","volume":"26","author":"Meyer","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2013.12.002_bib43","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/sj.npp.1301292","article-title":"Neurobehavioral and immunological consequences of prenatal immune activation in rats: Influence of antipsychotics","volume":"32","author":"Romero","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2013.12.002_bib44","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/mp.2008.44","article-title":"Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: Implications for the etiopathology of schizophrenia","volume":"15","author":"Romero","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib45","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1126\/science.1228261","article-title":"Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice","volume":"339","author":"Giovanoli","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2013.12.002_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/schbul\/2.1.19","article-title":"The dopamine hypothesis of schizophrenia: A review","volume":"2","author":"Meltzer","year":"1976","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2013.12.002_bib47","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib48","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: A review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0006-8993(98)00904-4","article-title":"Interleukin-2 and -6 induce behavioral-activating effects in mice","volume":"811","author":"Zalcman","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2013.12.002_bib50","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0006-8993(99)02063-6","article-title":"Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats","volume":"847","author":"Zalcman","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2013.12.002_bib51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-9-52","article-title":"Involvement of metabotropic glutamate receptor 5, AKT\/PI3K signaling and NF-kappaB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes","volume":"9","author":"Shah","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.biopsych.2013.12.002_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1176\/ajp.119.1.61","article-title":"Model psychoses and schizophrenia","volume":"119","author":"Luby","year":"1962","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib53","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib55","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1176\/ajp.156.10.1646","article-title":"Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia","volume":"156","author":"Adler","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2013.12.002_bib57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2013.12.002_bib58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.brainresbull.2010.04.006","article-title":"N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?","volume":"83","author":"Kantrowitz","year":"2010","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.biopsych.2013.12.002_bib59","doi-asserted-by":"crossref","first-page":"13957","DOI":"10.1523\/JNEUROSCI.4457-08.2008","article-title":"Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia","volume":"28","author":"Behrens","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2013.12.002_bib60","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2013.12.002_bib61","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1126\/science.1148045","article-title":"Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase","volume":"318","author":"Behrens","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2013.12.002_bib62","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1471-4159.2000.0750634.x","article-title":"The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK","volume":"75","author":"Tancredi","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.biopsych.2013.12.002_bib63","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1096\/fj.04-1625fje","article-title":"Interleukin-6: A cytokine to forget","volume":"18","author":"Balschun","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.biopsych.2013.12.002_bib64","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bbr.2003.12.018","article-title":"Cognitive function in young and adult IL (interleukin)-6 deficient mice","volume":"153","author":"Braida","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2013.12.002_bib65","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1073\/pnas.94.4.1500","article-title":"Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain","volume":"94","author":"Heyser","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2013.12.002_bib66","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1037\/0894-4105.12.3.426","article-title":"Neurocognitive deficit in schizophrenia: A quantitative review of the evidence","volume":"12","author":"Heinrichs","year":"1998","journal-title":"Neuropsychology"},{"key":"10.1016\/j.biopsych.2013.12.002_bib67","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib68","first-page":"S242","article-title":"Interleukin-6 and cognition in non-affective psychosis","volume":"39","author":"Miller","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2013.12.002_bib69","first-page":"1358","article-title":"Impact of antipsychotics on cytokine production in-vitro","volume":"45","author":"Himmerich","year":"2011"},{"key":"10.1016\/j.biopsych.2013.12.002_bib70","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib71","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3565(25)21237-X","article-title":"Peripheral-type benzodiazepine receptors: Autoradiographic localization in whole-body sections of neonatal rats","volume":"233","author":"Anholt","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2013.12.002_bib72","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/jcbfm.1991.64","article-title":"Macrophage and astrocyte populations in relation to [3H]PK 11195 binding in rat cerebral cortex following a local ischaemic lesion","volume":"11","author":"Myers","year":"1991","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2013.12.002_bib73","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ana.410240603","article-title":"Imaging of human brain lesions with an omega 3 site radioligand","volume":"24","author":"Benavides","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2013.12.002_bib74","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2967\/jnumed.109.066647","article-title":"Neuroinflammation in schizophrenia-related psychosis: A PET study","volume":"50","author":"Doorduin","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2013.12.002_bib75","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.biopsych.2008.04.025","article-title":"Microglia activation in recent-onset schizophrenia: A quantitative (R)-[11C]PK11195 positron emission tomography study","volume":"64","author":"van Berckel","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib76","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1017\/S1461145710000313","article-title":"Peripheral benzodiazepine receptors in patients with chronic schizophrenia: A PET study with [11C]DAA1106","volume":"13","author":"Takano","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2013.12.002_bib77","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.4088\/JCP.10m06745","article-title":"Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: A pathway to smaller hippocampal volume","volume":"72","author":"Mondelli","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib78","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.biopsych.2008.04.016","article-title":"Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults","volume":"64","author":"Marsland","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib79","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.biopsych.2010.08.027","article-title":"Searching for neuropathology: Gliosis in schizophrenia","volume":"69","author":"Schnieder","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib80","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0304-3940(99)00545-5","article-title":"Evidence for activation of microglia in patients with psychiatric illnesses","volume":"271","author":"Bayer","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.biopsych.2013.12.002_bib81","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jnen\/59.2.137","article-title":"Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics","volume":"59","author":"Radewicz","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.biopsych.2013.12.002_bib82","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00401-006-0090-8","article-title":"Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization","volume":"112","author":"Steiner","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.biopsych.2013.12.002_bib83","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1176\/appi.ajp.159.6.1029","article-title":"Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia","volume":"159","author":"Muller","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib84","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","article-title":"Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment","volume":"121","author":"Muller","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2013.12.002_bib85","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","article-title":"Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial","volume":"90","author":"Akhondzadeh","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2013.12.002_bib86","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.biopsych.2005.02.024","article-title":"Celecoxib augmentation of continuously ill patients with schizophrenia","volume":"57","author":"Rapaport","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib87","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib88","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00406-004-0478-1","article-title":"COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy","volume":"254","author":"Muller","year":"2004","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2013.12.002_bib89","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/0269881112444941","article-title":"Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment","volume":"26","author":"Chaudhry","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2013.12.002_bib90","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","article-title":"A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia","volume":"71","author":"Levkovitz","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib91","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","article-title":"Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials","volume":"39","author":"Nitta","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2013.12.002_bib92","doi-asserted-by":"crossref","unstructured":"Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS (2013): Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update [published online ahead of print Oct 8]. Schizophr Bull.","DOI":"10.1093\/schbul\/sbt139"},{"key":"10.1016\/j.biopsych.2013.12.002_bib93","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2013.12.002_bib94","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2013.12.002_bib95","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2013.12.002_bib96","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jad.2012.03.033","article-title":"Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study","volume":"141","author":"Abbasi","year":"2012","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2013.12.002_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002804","article-title":"Translating glutamate: from pathophysiology to treatment","volume":"3","author":"Javitt","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.biopsych.2013.12.002_bib98","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","article-title":"Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver","volume":"78","author":"Schobel","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2013.12.002_bib99","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.schres.2012.06.020","article-title":"Immunomodulatory effects of clozapine and their clinical implications: What have we learned so far?","volume":"140","author":"Roge","year":"2012","journal-title":"Schizophr Res"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000632231301069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000632231301069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:17:32Z","timestamp":1746058652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000632231301069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S000632231301069X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2013.12.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718244452.793490866","asserted-by":"object"}]},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}